Posted by Michael Wonder on 09 Sep 2022
FDA and EMA accept regulatory submission for Pfizer’s ritlecitinib for individuals 12 years and older with alopecia areata
9 September 2022 - Filings based on clinical data demonstrating significant scalp hair regrowth versus placebo.
Pfizer announced today that the US FDA accepted for filing the new drug application for ritlecitinib for adults and adolescents 12 years of age and older with alopecia areata.
